Related references
Note: Only part of the references are listed.cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets
S. L. Subramanian et al.
DIABETOLOGIA (2012)
Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients
Roberto Ciarcia et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Review Series - Inflammation & FibrosisFibrocytes and fibrosis
R. Bucala
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2012)
Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4 + T cells in the broncho-alveolar lavage of patients with systemic sclerosis
Anagha A. Divekar et al.
CLINICAL IMMUNOLOGY (2011)
Involvement of ATP-sensitive Potassium (KATP) Channels in the Loss of Beta-cell Function Induced by Human Islet Amyloid Polypeptide
Maud Soty et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
IL-1 Blockade Attenuates Islet Amyloid Polypeptide-Induced Proinflammatory Cytokine Release and Pancreatic Islet Graft Dysfunction
Clara Westwell-Roper et al.
JOURNAL OF IMMUNOLOGY (2011)
c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice
Gonzalo I. Cancino et al.
NEUROBIOLOGY OF AGING (2011)
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes
Dariush Mokhtari et al.
CLINICAL SCIENCE (2010)
Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?
S. Zraika et al.
DIABETOLOGIA (2010)
Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo
Mandy L. Ballinger et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?
Stephen Fitter et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A Protein Tyrosine Kinase Inhibitor, Imatinib Mesylate (Gleevec), Improves Erectile and Vascular Function Secondary to a Reduction of Hyperglycemia in Diabetic Rats
Serap Gur et al.
JOURNAL OF SEXUAL MEDICINE (2010)
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia
Stefania Mariani et al.
LEUKEMIA RESEARCH (2010)
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease
Gen He et al.
NATURE (2010)
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Jeffrey A. Bluestone et al.
NATURE (2010)
Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice
Myoung Sook Han et al.
DIABETES (2009)
Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes
Peter J. Little et al.
THESCIENTIFICWORLDJOURNAL (2009)
IRS1-independent defects define major nodes of insulin resistance
Kyle L. Hoehn et al.
CELL METABOLISM (2008)
Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet
Robert Hagerkvist et al.
CLINICAL SCIENCE (2008)
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib
Elizabeth Day et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Ultrastructure of islet microcirculation, pericytes and the islet exocrine interface in the HIP rat model of diabetes
Melvin R. Hayden et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-β increases migration of aortic smooth muscle cells
Noboru Akiyama et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2008)
Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)
Apostolos Tsapas et al.
LEUKEMIA RESEARCH (2008)
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
M. Breccia et al.
LEUKEMIA RESEARCH (2008)
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cedric Louvet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Remission of diabetes while on sunitinib treatment for renal cell carcinoma
A. Templeton et al.
ANNALS OF ONCOLOGY (2008)
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
Taira Maekawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
Isletopathy in type 2 diabetes mellitus: Implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress
Melvin R. Hayden et al.
ANTIOXIDANTS & REDOX SIGNALING (2007)
Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy
Kari K. Eklund
IMMUNOLOGICAL REVIEWS (2007)
Amelioration of diabetes by imatinib mesylate (Gleevec®):: role of β-cell NF-κB activation and anti-apoptotic preconditioning
Robert Hagerkvist et al.
FASEB JOURNAL (2007)
Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro
Robert Hagerkvist et al.
CELL BIOLOGY INTERNATIONAL (2006)
Sensing extracellular matrix: An update on discoidin domain receptor function
Wolfgang F. Vogel et al.
CELLULAR SIGNALLING (2006)
Population pharmacokinetics of imatinib and the role of α1-acid glycoprotein
N. Widmer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib
Daniel B. Costa et al.
DIABETES CARE (2006)
Stem cell factor and its receptor c-Kit as targets for inflammatory diseases
L Reber et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
The vascular basement membrane:: A niche for insulin gene expression and β cell proliferation
G Nikolova et al.
DEVELOPMENTAL CELL (2006)
Role of islet amyloid in type 2 diabetes mellitus
JWM Hoppener et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes -: Many differences, few similarities
M Cnop et al.
DIABETES (2005)
Reversal of experimental pulmonary hypertension by PDGF inhibition
RT Schermuly et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Platelet-derived growth factor receptor-β (PDGFR-β) activation promotes its association with the low density lipoprotein receptor-related protein (LRP) -: Evidence for co-receptor function
CS Newton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation
JF Paulsson et al.
DIABETES (2005)
Imatinib and regression of type 2 diabetes
D Veneri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Imatinib attenuates diabetes-associated atherosclerosis
M Lassila et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Imatinib mesylate may improve fasting blood glucose in diabetic Ph plus chronic myelogenous leukemia patients responsive to treatment
M Breccia et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes -: Evidence for role of islet amyloid formation rather than direct action of amyloid
AE Butler et al.
DIABETES (2003)
Glucose-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent upregulation of the platelet-derived growth factor-β receptor potentiates vascular smooth muscle cell chemotaxis
M Campbell et al.
DIABETES (2003)
Inactivation of NF-κB-dependent cell survival, a novel mechanism for the proapoptotic function of c-abl
H Kawai et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Aph2, a protein with a zf-DHHC motif, interacts with c-Abl and has pro-apoptotic activity
BJ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation
Z Goldberg et al.
EMBO JOURNAL (2002)
Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell
Y Arita et al.
CIRCULATION (2002)
Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-β-D-arabinofuranosylcytosine
D Raina et al.
MOLECULAR PHARMACOLOGY (2002)
Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease
B Scheijen et al.
ONCOGENE (2002)
c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage
K Yoshida et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis
DL Eizirik et al.
DIABETOLOGIA (2001)
Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced Apoptosis
Y Ito et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
T Yamauchi et al.
NATURE MEDICINE (2001)
Targeting of the c-Ab1 tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress
S Kumar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species
XG Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines
S Janciauskiene et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
